CorAssist Cardiovascular - Innovative Solutions for Diastolic Heart Failure (DHF)
CorAssist is pioneering the treatment of
Diastolic Heart Failure (DHF) patients
CorAssist Cardiovascular - Innovative Solutions for Diastolic Heart Failure (DHF)

Executive Staff

Yaron Tal, President & CEO

Yaron Tal brings to CorAsssit more than 19 years of extensive experience in general management, investments and fund raising, market strategy and M&A's mainly in the field of medical devices and clean tech. Prior to CorAssist , Mr. Tal served as President and CEO of TopSpin Medical Inc. and prior to that, as President and CEO of Galil Medical Ltd. Mr. Tal also served as CFO and Acting Manager of DEP Technology Holding Ltd, the investment arm of Elron Electronic Industries Ltd and Discount Investments Corporation Ltd. Mr. Tal began his professional career in the offices of Prof Itzhak Swary & Co Financial Consulting, and has since accumulated significant experience in company valuation and M&A’s. Mr. Tal holds an MBA from Ben Gurion University, a BA in Economics and Accounting from the Hebrew University in Jerusalem, and an Israeli CPA license.

Lea Lak MD, VP & Medical Director

Dr. Lak was previously the medical manager of Polyheal Ltd, where she developed a device to assist wound healing, and the medical specialist developing coronary artery anastomotic devices at ByPass Ltd. Dr. Lak received her medical degree from the Hebrew University of Jerusalem.

Lior Rosen, VP R&D

Mr. Rosen brings with him broad managerial experience in leading multi-disciplinary projects. In his previous position, he served as a senior R&D project manager at Power Paper Ltd. His expertise includes computational bio-fluid dynamics with specialization on cardiovascular blood flow analysis. Mr. Rosen holds a BSc in Mechanical Engineering from the Technion Israel Institute of Technology and a MSc in Biomedical Engineering from Tel Aviv University.

Amir Sherman DVM, PreClinical Research Manager

Prior to joining CorAssist Dr. Sherman served as a pre clinical study manager at TransPharma-Medical, where he was in charge on preclinical trials in the field of transdermal drug delivey. Dr. Sherman's clinical expertise include general veterinary internal medicine and surgery, experimental work with large animals and other laboratory animals, and experience in developing animal models, pharmacokinetics and pharmacodynamics. Dr. Sherman has a DVM degree from the Hebrew university of Jerusalem.